Skip to main content
Premium Trial:

Request an Annual Quote

CORRECTED: Tranzyme to Produce Cell Lines for Gentris with PGx Applications

This article has been corrected. In a previous version, the name "Gentris," was misspelled and the headline was unclear.

 

NEW YORK, June 24 (GenomeWeb News) - North Carolina biotechnology companies Tranzyme Pharma and Gentris said today that they are collaborating to develop cell lines intended to serve as genetic controls for diagnostic assays used to gauge patients' responses to drug treatments.

 

Morrisville-based Gentris will provide Tranzyme, located in ResearchTrianglePark, with genetic sequences relating to rare, clinically relevant alleles that are implicated in the metabolism of therapeutic compounds, according to an official company statement. Tranzyme will then use its functional biology and gene delivery technology, called TExT, to create recombinant human cell lines expressing the genetic sequences. Financial terms of the deal were not disclosed.

 

In addition, the companies said that they will jointly own the cell lines, and may eventually enter into an additional agreement to commercialize them as genetic controls for FDA-approved diagnostic assays.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.